Extract to table

1(a) of the Exclusive License Agreement dated October 2, 2023 (the "License Agreement") between Licensor and Licensee, relating to the exclusive worldwide license to develop, manufacture, and commercialize the pharmaceutical compound designated PPC-4187 (Penteracitinib), which upfront payment is required to be held in escrow pending the satisfaction of certain closing conditions as more fully described in the Escrow Agreement and the License Agreement

Conditions for Release The Escrow Deposit shall be released from the Escrow Account to Penterra Pharmaceuticals Corp

In the event that the closing conditions are not satisfied, and the Escrow Deposit is not released, on or prior to the Scheduled Closing Date (as may be extended), the Escrow Deposit shall be returned to Licensee in accordance with Section 3

Such fees shall be payable in accordance with the terms set forth in Section 5

As specified therein, the initial acceptance fee and the first quarterly maintenance fee shall be borne equally by Licensor and Licensee, with each party responsible for one-half of such amounts

Governing Terms and Definitions All capitalized terms used but not otherwise defined in this letter shall have the respective meanings ascribed to such terms in the Escrow Agreement